United States securities and exchange commission logo





                            August 8, 2020

       Iain Ross
       Executive Chairman
       Silence Therapeutics plc
       72 Hammersmith Road
       London W14 8TH
       United Kingdom

                                                        Re: Silence
Therapeutics plc
                                                            Amendment No. 1 to
Draft Registration Statement on Form F-1
                                                            Submitted July 31,
2020
                                                            CIK No. 0001479615

       Dear Mr. Ross:

             We have reviewed your amended draft offering statement and have
the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

               Please respond to this letter by providing the requested
information and either submitting
       an amended draft offering statement or publicly filing your offering
statement on EDGAR. If
       you do not believe our comments apply to your facts and circumstances or
do not believe an
       amendment is appropriate, please tell us why in your response. After
reviewing any amendment
       to your draft offering statement or filed offering statement and the
information you provide in
       response to these comments, we may have additional comments.

       Amendment No. 1 to Draft Registration Statement on Form F-1

       Business
       Overview, page 61

   1.                                                   We note your response
to prior comment 2; however, you continue to state conclusions
                                                        regarding efficacy.
Please revise your statements here and on page 48 that your product
                                                        candidate SLN360
"silences" genetically controlled expression of Lipoprotein(a), your
                                                        product candidate
SLN124 "silences" TMPRSS6 gene expression and your SLN500
                                                        program candidates
"silence" C3. You may present objective data resulting from your
                                                        trials without
including conclusions related to efficacy in the Business section.
 Iain Ross
FirstName   LastNameIain
Silence Therapeutics plc Ross
Comapany
August      NameSilence Therapeutics plc
        8, 2020
August
Page  2 8, 2020 Page 2
FirstName LastName
SLN124 reduced transferrin saturation in -thalassemic mice compared to
deferiprone, page 72

2.       We note your response to prior comment 10. Please revise to provide
the basis for your
         statement that similar magnitudes of increase in hemoglobin levels are
associated with
         "clinically meaningful" improvement in health related quality of life
measures in humans.
       You may contact Jenn Do at (202) 551-3743 or Al Pavot at (202) 551-3738
if you have
questions regarding comments on the financial statements and related matters.
Please contact
Ada Sarmento at (202) 551-3798 or Joe McCann at (202) 551-6262 with any other
questions.



                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences